Global Cardiac Biomarkers Market - Segmented by Type Of Marker, Application, Location Of Testing and Geography - Growth, Trends, and Forecast (2022 - 2030)
The cardiac biomarkers market is expected to register a CAGR of about 18.5%, during the forecast period. Biomarkers have an essential role in the diagnosis, management, risk stratification, and clinical decision-making in the patients suffering from disease. Cardiac biomarkers are measurable and quantifiable biological parameters, which are detected in the blood and serve as indices for physiological and pathological assessment by a specialized immunoassay.
Increasing Prevalence of Cardiovascular Diseases
Myocardial infarction is caused is one of the conditions that occur due to cardiovascular diseases. It causes significant mortality and morbidity. Timely diagnosis of heart conditions allow clinicians to analyze the risk of their patients and prescribe relevant treatment. Biomarkers enable us for timely identification of cardiovascular conditions and help patients prevent conditions, like myocardial infarction and acute coronary syndrome. Increasing awareness about early diagnosis using cardiovascular biomarkers among patients and healthcare providers, along with factors, like growing funding from public and private organizations for R&D and technological advancements using cardiac will drive the market in the forecasted period.
Stringent Regulation
After the identification of a biomarker data from the discovery tools indicate that it may answer the clinical question posed, its successful translation will require an assay that must meet stringent requirements. This step represents a critical cause of failure for biomarkers, as the development of a robust and reproducible assay, with appropriate sensitivity, specificity, and precision, depends on a standards-based discovery process. For assays to be submitted for FDA qualification or clinical validation the test must be analytically validated and, depending on the targeted clinical application, evaluated in one or more clinical trials. Finally, as the assay moves to later discovery, it is important to define how clinical decision making will be impacted by the assay, and increasingly careful considerations to the economics of manufacturing, competing technologies, and scale must also be considered. All these steps require a lot of time and slow down the overall development process. Other factors, such as poor reimbursement policies will restrain the market growth.
Geographical or Segment Scenario
North America is projected to lead the global market, as there is a high demand for testing due to high rate of CVD prevalence and growing awareness towards application cardiac biomarkers in cardiac diagnostics. Asia-Pacific is estimated to register the fastest CAGR owing to the increasing disposable incomes, affordable solutions, and increased funding in R&D in the field advanced cardiac treatments.
Key Developments in the Market
• January 2017 - Roche announced that it has received the 510(k) clearance for its Elecsys Troponin T Gen 5 STAT (TnT Gen 5 STAT) blood test for patients with a suspected heart attack
Major players – ALERE INC., BECKMAN COULTER, BECTON, DICKINSON AND CO., BIOMERIEUX, BIO-RAD LABORATORIES, RANDOX LABORATORIES, ROCHE DIAGNOSTICS CORPORATION, SIEMENS HEALTHCARE AND THERMO FISHER SCIENTIFIC, amongst others.
Reasons to Purchase this Report
• Current and future cardiac biomarkers market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
Increasing Prevalence of Cardiovascular Diseases
Myocardial infarction is caused is one of the conditions that occur due to cardiovascular diseases. It causes significant mortality and morbidity. Timely diagnosis of heart conditions allow clinicians to analyze the risk of their patients and prescribe relevant treatment. Biomarkers enable us for timely identification of cardiovascular conditions and help patients prevent conditions, like myocardial infarction and acute coronary syndrome. Increasing awareness about early diagnosis using cardiovascular biomarkers among patients and healthcare providers, along with factors, like growing funding from public and private organizations for R&D and technological advancements using cardiac will drive the market in the forecasted period.
Stringent Regulation
After the identification of a biomarker data from the discovery tools indicate that it may answer the clinical question posed, its successful translation will require an assay that must meet stringent requirements. This step represents a critical cause of failure for biomarkers, as the development of a robust and reproducible assay, with appropriate sensitivity, specificity, and precision, depends on a standards-based discovery process. For assays to be submitted for FDA qualification or clinical validation the test must be analytically validated and, depending on the targeted clinical application, evaluated in one or more clinical trials. Finally, as the assay moves to later discovery, it is important to define how clinical decision making will be impacted by the assay, and increasingly careful considerations to the economics of manufacturing, competing technologies, and scale must also be considered. All these steps require a lot of time and slow down the overall development process. Other factors, such as poor reimbursement policies will restrain the market growth.
Geographical or Segment Scenario
North America is projected to lead the global market, as there is a high demand for testing due to high rate of CVD prevalence and growing awareness towards application cardiac biomarkers in cardiac diagnostics. Asia-Pacific is estimated to register the fastest CAGR owing to the increasing disposable incomes, affordable solutions, and increased funding in R&D in the field advanced cardiac treatments.
Key Developments in the Market
• January 2017 - Roche announced that it has received the 510(k) clearance for its Elecsys Troponin T Gen 5 STAT (TnT Gen 5 STAT) blood test for patients with a suspected heart attack
Major players – ALERE INC., BECKMAN COULTER, BECTON, DICKINSON AND CO., BIOMERIEUX, BIO-RAD LABORATORIES, RANDOX LABORATORIES, ROCHE DIAGNOSTICS CORPORATION, SIEMENS HEALTHCARE AND THERMO FISHER SCIENTIFIC, amongst others.
Reasons to Purchase this Report
• Current and future cardiac biomarkers market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
